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With general population ageing, the impact of age on health care expenditures has largely been 
discussed as predictions represent a threat to national health services. The term steepening refers 
to the fastest growth of per capita health care expenditures of the elderly, a phenomenon that if 
confirmed can cause unprecedented increases in public spending. The goal of this work is to test 
for the existence of steepening on Portuguese NHS hospital inpatient care episodes between 2009 
and 2018. Initial results suggest a non-rejection of the stated hypothesis. With the inclusion of 
mortality, results on steepening are reduced indicating part of the increase in health care 










Over the last decades there has been a remarkable change in population structures for most 
countries. The increase in life expectancy and the reduction in both birth and mortality rates have 
contributed for the overall ageing of societies. By the beginning of 2019, individuals over 65 years-
old were 20.3% of the total population from European Union countries (EU-27). Under this 
context, Portugal stood as the 3rd country with the highest share of elderly population, around 
21.8%, that in comparison with a decade before represents 3.8 percentual points increase. Amongst 
other indicators, EU projections establish an even higher relative growth in the number of 
individuals aged above 65 years-old, causing the old-age dependency ratio to reach twice the value 
registered today, meaning there will be on average less than 1 active person per each individual 
with more than 65 years-old, by 2100. (Eurostat 2020) 
Such prospects carry along consequences to countries’ public health care services and spending, 
not solely with the rise of expenditures but also on structural issues as the type of care provided or 
the financing scheme used so far. In Portugal, the National Health Service (NHS) is mostly 
financed by general taxation revenue and its spending has consistently been growing, apart from 
the financial crisis cut back, accounting for 9-10% of GDP. (INE 2020) (INE 2012) It is now a 
concern that demographic trends as the population ageing alongside with the constant demand for 
larger technological advances on medicines and treatments will push for an even faster growth of 
national health care expenditures, particularly in the public sector.  
The goal of the present work is to assess the impact of the Portuguese population ageing on the 
growth of health expenditures with NHS hospital inpatient care. This study will use the concept of 
steepening, firstly introduced by Buchner and Wasem (2006) as the fastest growth on health care 
expenditures for older groups of the population than for the remaining individuals, and test for its 
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presence in the Portuguese NHS inpatient hospital records from 2009 to 2018. The dataset follows 
the Diagnosis Related Groups (DRG) framework to classify the patient hospitalization cause and 
expenditures will be computed using the reference weights set by the DRG coding system. As for 
the methodology chosen to test steepening, it is based on previous case-studies made in 
Switzerland, Germany and Norway that included three different approaches to the concept, 
resulting in three distinct models that allow not only for general results on the growth rate of care 
expenditures for the elderly but also for age-specific conclusions.  
The application of this methodology to the Portuguese case represents a new contribution for the 
topic discussion. As costs on health care are expected to continue to increase, it is of most interest 
to understand if in the past there were any age-patterns on expenditures or if particular morbidities 
were the cost-drivers. Knowing this, it is possible to anticipate what will happen in the next decades 
and develop a strategy to guarantee the NHS viability, for instance by redirecting investment to 
cost improvement actions or emphasize the importance of morbidity prevention to avoid higher 
expenditures later on.    
The paper is organized as follows: section II will be devoted to a review on the relevant literature 
and empirical work in this topic; next, on section III there will be a description of the data selected 
for the work, followed by a detailed revision and introduction of the methodology chosen to 
address the research question on section IV. Section V will firstly cover some descriptive results 
on the variables of interest and then present the steepening results for the three models. Finally, 
there will be a discussion upon the results obtained and what conclusions are possible to retrieve 





II. LITERATURE REVIEW 
The discussion upon the consequences of an ageing population for general health care expenditures 
has been marked by two opposite stands. On one hand, some predict ageing of the population to 
lead to an increase of per capita health expenditures in the future due to the strong correlation 
between age and time – steepening hypothesis. Others believe health care expenditures are 
independent of age and by excluding the impact of ageing, health care spending should decrease 
because of the mortality compression and increase in length of life observed in the last decades – 
red herring hypothesis. Although the two are contradictory at first, it is important to unveil the 
underlying assumptions behind these terms and eventually find a common ground in both.  
From a conceptual perspective, health care expenditures are considered to be influenced by 
individual and societal determinants. As one of the individual factors, age is classified as a 
predisposing element meaning it may not be the essential reason for the health care demand, but 
different age groups have distinct amounts of the need factor for it - illness or poor health status. 
These patterns generate consumption profiles for each age or age group, usually named as age-
profiles of health care expenditures. (de Meijer, et al. 2013) Even though these can be affected by 
a variety of factors, over the last few years, empirical studies drew two possible scenarios for the 
prevalence of morbidity in future societies. On one side, as living conditions improve and people 
endorse healthier lifestyles, health care expenditures will probably decrease as they approach older 
stages in life and eventually their last years – morbidity compression. (Fries 1983) Nonetheless, it 
is also true, access to health care is expanding so people from all age groups will tend to seek for 
more care services shifting their consumption profile up and resulting in general higher 
expenditures in health – morbidity expansion. (Olshansky, et al. 1991)  
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The steepening hypothesis introduced by (Buchner and Wasem 2006) suggested an 
underestimation of future health spending as changes in those expenditure profiles were not being 
acknowledged. In their work, authors argued for a faster growth in per capita health care 
expenditures in elder groups of population compared with younger and middle-aged individuals 
that led to a steepening of the age-profiles. The causes behind were poorly described but relied 
essentially over the argument of the prevalence of chronic diseases being expanding amongst older 
groups and technological improvements associated with these morbidities driving higher per capita 
costs. 
Later, (Felder and Werblow 2008) argued for the importance of including both effects of the 
increased length of life and morbidity compression in the steepening analysis as evidence predicted 
relatively lower per capita health care costs associated with death at later stages in life which would 
flatten the age-profile of the elderly. These impacts were captured by including mortality rates to 
the testing models and although authors did not find evidence for steepening in Swiss cantons data, 
they continued to recognize the ageing process as a threat to the reliability and functioning of the 
national health systems that are publicly financed, just as Buchner and Wasem did.   
With a different perspective on the correlation between health care expenditures and age, the red 
herring hypothesis, formulated by (Zweifel, Felder and Meiers 1999), predicts a more optimistic 
scenario for the next years. Under this framework, population ageing is described rather as a 
“distractive” determinant for future health expenditures and focus should rely on the impact of the 
final years of a person’s life on these, also referred as the “time-to-death”. In fact, authors believed 
age would only influence as a predisposing element whereas this “time-to-death” would largely 
be the responsible for the rise in care expenditures, especially at younger individuals once death-
related expenses are expected to be significantly higher, in comparison with older patients. In this 
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sense, red herring’s view over the future comes acknowledging the ongoing expansion of the 
average lifetime which typically postpones the moment of death to older stages and results in 
relatively lower health care expenditures.  
Despite the clear contrast between these two definitions, (Gregersen 2014) claimed for an 
independent relationship between them as each frame health care expenditures differently 
assuming conditions that are not mutually exclusive. However, proving the existence of both 
phenomena requires different sets of data, as the “time-to-death” indicator is only achievable on a 
longitudinal panel.  
Due to this data constraint, the present work will only address the first concept – steepening –
elaborating a cross-sectional study for the Portuguese case, following similar approaches as 
previous case-studies. Section IV provides additional revision on the methodology developed.    
 
III. DATA 
To perform the analysis of the Portuguese case, two data sources will be used. The first consists in 
a cross-sectional data with public hospital annual admissions from 2009 to 2018. Provided by the 
ACSS,1 each observation contains information on a hospitalization episode, displaying details on 
the year, number of days the patient received inpatient care and respective unit, gender, age, 
residential area of the individual, and the DRG code associated with the patient admission. From 
here, only observations with one or more days of hospitalization will be considered. As no personal 
identification number is provided, patients are not identifiable on the records which makes it 
impossible to track them over the period. In addition, hospital registration is mandatory for public 
 
1 Administração Central do Sistema de Saúde 
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units so the only self-selection concern in this dataset is the patient’s decision upon receiving care 
in a public or private hospital.   
To this data, it will be added, from PORDATA, statistics on the number of residents and the 
number of decedents in Portugal from 2009 to 2018, by each NUTS level III and age group. 
(PORDATA 2020) (PORDATA 2020) 
The Diagnosis Related Groups coding system is a hospital classification for patients with similar 
clinical conditions from a resource consumption point of view. Each group has associated a relative 
cost of the full patient treatment given the expected resources needed for the specific pathology. 
Originally created in the United States in the 70’s, this system has been used in the Portuguese 
health system since 1990 as a record and public providers reference tool. Since then, a few reforms 
occurred to the DRG version in practice. (ACSS 2020) Relevant for the following study are the 
changes made in 2006 for AP-DRG 21, later in 2013 for AP-DRG 27 and the last one in 2015 for 
an APR-DRG 31. Prior to 2015, the modification involved merely an update on the relative weights 
of each diagnosis group in monetary terms. (ACSS 2013)  
However, with the reform introduced in 2015, the coding system adopted switched from an All-
Patient classification to All Patient Refined (APR) allowing for further discrimination on the 
relative cost weights based on four levels of severity and mortality risks. As a result, there was a 
significant change in the price level associated with each DRG relative cost weight when 
comparing to prior versions, as it is possible to confirm on Table 1 at Appendix section.   (ACSS 





MERGING THE DATASETS  
As there was no original variable on the cost of each episode at the ACSS data, the first step in 
building the dataset was to generate a new variable indicating the correspondent expenditure. 
Information on the full inpatient care “price” for each clinical group was available to all DRG 
versions, allowing to index these references costs to every observation. To such, an algorithm 
indicating the Major Diagnostic Category (MDC) and the respective DRG group was created and 
labelled as “Cod_Pay”. This variable worked as an auxiliary variable and will not be used for any 
inference purpose. From here, the variable “Pay_Int” was generated to all observations, 
displaying the total relative cost of the hospitalization for each patient.  
Recognising for the structural change on the coding system, a second dataset was generated 
making the conversion of newest versions to the baseline (AP-DRG 21) and using as reference its 
own price table for all the remaining years. The goal is to try and remove a possible price effect 
originated from these reforms and confront the two scenarios – with and without price correction- 
throughout the study. With this step, a number of observations were lost as some of the new codes 
in the latest reforms were classified as “invalid diagnostics” once there was not a direct link to the 
first version.  
Moving on, for the years of 2009 and 2010, the variable “age” had to be created based on 
the “Date of Birth”. Whereas from 2014 onwards, information regarding the patient residency 
area had to be transformed into a string variable since it was in a numeric format.  
The next stage was to merge the ACSS and the PORDATA datasets using the residency area. Here, 
there was a problem on the geographical difference between “district” and each NUTS level III 
described on both databases. Because it was being measured in two distinct units, a new 
variable “nutsiii” was generated on the ACSS files that returned the corresponding NUTS level 
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III to the residency area indicated. (Diário da República 2013) Undertaking this methodology, a 
significant number of observations  had no information for the residence area, so in order 
to avoid eliminate these episodes, the patient residency was assumed to be in the same region as 
the hospital where the admission occurred. Although it was necessary not 
to lose observations, assigning the hospital NUTS level III to the patient residency can raise a 
possible bias on the sample given that for specific pathologies or hospitals there are a lot 
of displaced patients due to lack of treatment near home or treatment necessities.  
Having the dataset all built, the total number of observations is 6.811.607 which can be grouped 
into ten years, 22 five-year-old gap age groups, two genders, 25 NUTS level III and 26 DRGs. 
Further along, episodes of births, pregnancy and neonatal care labelled in DRG 14 and 15 will be 
excluded to perform the steepening analysis as these are not entirely representative of a disease.  
Additionally, it is important to highlight the uneven distribution of observations throughout the 
years as around 58% of the episodes were registered during the first five years of the period in 
analysis. One possible but most likely not exclusive explanation is the high investment and 
development made in outpatient surgery that reduced in large scale the need for the patient to stay 




Following the relevant literature and previous case studies, the steepening analysis will be 
performed with three different models. The inclusion of more than one model allows for a wider 
range of interpretations on the impact of ageing on health care expenditures when concerning 
different age groups and the inclusion of other explanatory factors.  
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Any result on the impact of age in health care spending can obviously combine various effects. 
For instance, in case of reaching a conclusion that older people spend more than younger, the 
question remains if it is due to higher consumption of care services, higher percentage of older 
people in that society or if the most frequent morbidities for this age group are more costly to treat. 
To try and disentangle these three dimensions, a price analysis across DRG groups as well as the 
use of a per capita variable for the health care expenditures will be considered.  
The first model – Model A - was developed by (Buchner and Wasem 2006) and it is mainly the 
mathematical translation of the steepening definition introduced in their work. Observations are 
split between two groups - old and young - at the age threshold of 65 years-old, for every region 
(NUTS III). Then an annual ratio between the per capita expenditures of the two groups – here 
denominated as Ratio A - is regressed on the variable “year”, as follows:  
 
(1) 𝑅𝑎𝑡𝑖𝑜 𝐴 𝑦𝑒𝑎𝑟,𝑟𝑒𝑔𝑖𝑜𝑛  =
?̅?𝑎𝑔𝑒𝜖[65,118],𝑦𝑒𝑎𝑟,𝑟𝑒𝑔𝑖𝑜𝑛
?̅?𝑎𝑔𝑒𝜖[5,64],𝑦𝑒𝑎𝑟,𝑟𝑒𝑔𝑖𝑜𝑛
=  𝜆0 + 𝜆1 ∗  𝑦𝑒𝑎𝑟 
 
 
This model allows for the elimination of any inflation effect present on the sample due to the three 
price adjustments that created a price-effect on the per capita expenditure variable. As this change 
was not constant to all diagnostic groups, (1) will be run twice – first with the actual expenditures 
and secondly with the price correction already mentioned.  
A more interesting strategy is to have an age group specific analysis, instead of an age-cut between 
old/young. Suggested by the same authors, Model B is an adaptation of the prior model in which 
Ratio B gives the balance between each age group per capita expenditures and a benchmark group. 
Once again, the unit of observation is obtained by year, age group and region using as reference 
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the Metropolitan Area of Lisbon. Here, the age reference group will be individuals aged between 
5 to 9 years old.  
(2) 𝑅𝑎𝑡𝑖𝑜 𝐵𝑎𝑔𝑒𝑔,𝑦𝑒𝑎𝑟,𝑟𝑒𝑔𝑖𝑜𝑛 =
?̅?𝑎𝑔𝑒𝑔,𝑦𝑒𝑎𝑟,𝑟𝑒𝑔𝑖𝑜𝑛
?̅?𝑏𝑒𝑛𝑐ℎ𝑚𝑎𝑟𝑘,𝑦𝑒𝑎𝑟,𝑟𝑒𝑔𝑖𝑜𝑛
=  𝛽0,𝑎𝑔𝑒𝑔 + 𝛽1,𝑎𝑔𝑒𝑔 ∗  𝑦𝑒𝑎𝑟 
This standardisation attributes a new interpretation to the respective coefficients – now each 
reflects the age group average annual growth rate of the per capita expenditure relative to the 
annual growth rate of the benchmark group. Another advantage of this approach concerns with the 
additional knowledge on the behaviour of other age classes other than older ones. (Buchner and 
Wasem 2006) 
As seen in equations (1) and (2), a linear relationship is assumed between health care expenditures 
and age. Nonetheless, as it will be shown in section V, data seems to suggest for a non-linear 
association between the two. On the same note, both (Buchner and Wasem 2006) and (Felder and 
Werblow 2008) modelled an exponential relationship between the per capita health care 
expenditures and age and recognized the steepening hypothesis could not be properly tested only 
by including one explanatory variable to care spending. Therefore, Model C contemplates the 
effect of time, gender, mortality rates and age on natural logarithm of health care expenditures. 
Once the unit of observation (i) is defined by age group, gender, year and region, a set of 24 dummy 
variables for region will also be added to the regression as follows:  
 
(3) ln(?̅?𝑖) = γ + 𝛿 ∗ 𝑓𝑒𝑚𝑎𝑙𝑒𝑖 + ∑ 𝜐𝑎
10
𝑎=0 ∗ 𝑎𝑔𝑒𝑔𝑟𝑜𝑢𝑝𝑎 + ∑ 𝜏𝑎
9
𝑎=0 ∗ 𝑎𝑔𝑒𝑔𝑟𝑜𝑢𝑝𝑎 ∗ 𝑓𝑒𝑚𝑎𝑙𝑒𝑖 +
∑ 𝛽r ∗  𝑟𝑒𝑔𝑖𝑜𝑛𝑟
24
r=0 + θ ∗ 𝑦𝑒𝑎𝑟𝑖 + ∑ 𝜅x
4
𝑥=1 ∗ (𝑚𝑟𝑎𝑡𝑒𝑖)
𝑥 +  ∑ 𝜌𝑎
9




The variable “female” is a dummy for gender that takes value 1 if the patient is a female and zero 
if male so 𝛿  must be interpreted as the marginal increase on per capita expenditures of women 
compared to men. As for coefficients on variable “agegroup”, each indicates the relative effect of 
belonging to an age group when compared with the benchmark group of individuals aged between 
5-9 years old. Additional to the original model, (3) also distinguishes the contribution of female 
individuals’ health care expenditures to the overall performance of the age cohort, captured by the 
ten cross terms between “agegroup” and “female” dummies. As for the impact of regional 
differences, coefficients β measure the marginal effect of living in a specific area in comparison 
with the Metropolitan Area of Lisbon.  
More interesting are the interpretations for coefficients 𝜃 and 𝜌𝑎 . The inclusion of the interaction 
term between variables “agegroup” and “year” allows the model to capture the yearly growth 
rates of each age group expenditures. Therefore, any coefficient  𝜌𝑎 should be evaluated as the 
difference between the annual growth rate, measured by θ, and that age group rate. Finally, 𝜅x 
retributes the increase on care spending derived by the mortality rate registered for the patient’s 
age class in his/her area of residence.  
The inclusion of mortality rates to the approach seems rather crucial as it has already been proved 
the significant increase in health care expenses on the year before death. Once these costs tend to 
be higher in relative younger individuals, the increase in the length of life in the past decades and 
the reduction in mortality rates will also likely “delay” and reduce expenditures on the last year-to 
death. (Zweifel, Felder and Meiers 1999). Therefore, it is possible that some of changes in health 
care expenditures of a specific age group are due to changes on its respective mortality level. For 
instance, if individuals aged between 60 and 70 have lower morbidity levels and consequently 
lower mortality rates, then it is expected that their care expenditures are also relatively lower as 
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death-related costs are diminished. In very broad terms, these mortality-related variables try to 
capture a similar effect as the “time-to-death” dimension introduced in the red herring hypothesis. 
In addition, mortality levels can also be related to health care demand. Once the share of population 
seeking for hospital treatment increases, the number of deaths is expected to decrease, in particular 
at older stages in life. This will naturally imply an increase in per capita health care expenditures.  
To better understand how the model in (3) can help on testing the steepening hypothesis, it might 
be useful to go back to the essence of what the term stands for– the fastest growth of health care 
expenditures for older groups in comparison with the rest of the population. With this concept in 
mind, (Felder and Werblow 2008) redefined the mathematical expression for steepening as the 
cross derivative of health care expenditures with respect to variables age (a) and year (y):  
  (4)  
𝜕2𝑙𝑛(𝑌?̅?(𝑎,𝑦))
𝜕𝑎𝜕𝑦
> 0 , 
meaning that if the change in growth rate of per capita expenditures is positively affected by the 
increase in age and as the years go by then there is evidence for steepening in the sample. 
Additionally, they also argue steepening to be affected by the changes in mortality levels caused 
by changes in age profile throughout years.  (Felder and Werblow 2008) To know the magnitude 
of these age and time effects on mortality rates, the first step relies on running the following:  
(5) 𝑚𝑟𝑎𝑡𝑒𝑖 = 𝛼0 + 𝛼1 ∗ 𝑦𝑒𝑎𝑟𝑖 ∗ 𝑎𝑔𝑒𝑖 + 𝛼2 ∗ 𝑎𝑔𝑒𝑖 + 𝛼3 ∗ 𝑦𝑒𝑎𝑟𝑖 + 𝑖 
From here and going back to (3), the steepening proposition would not be rejected if the difference 





=  𝜌𝑎+1 −  𝜌𝑎 + ∑ 𝜅x(𝛼1)
𝑥4




The use of a polynomial function of power four to address the mortality effect on health care 
expenditures is poorly described by the authors and ends up being dropped later on by (Gregersen 
2014) that suggested including solely the effect of mortality rates to the power of 1 on Model C 
as well as other mortality-related variables to capture the real impact of it.  
As such, cross terms between mortality rate and age and mortality rate and year were added to the 
model: 
(7) ln(?̅?𝑖) = γ + 𝛿 ∗ 𝑓𝑒𝑚𝑎𝑙𝑒𝑖 + ∑ 𝜐𝑎
9
𝑎=0 ∗ 𝑎𝑔𝑒𝑔𝑟𝑜𝑢𝑝𝑎 + ∑ 𝜏𝑎
9
𝑎=0 ∗ 𝑎𝑔𝑒𝑔𝑟𝑜𝑢𝑝𝑎 ∗ 𝑓𝑒𝑚𝑎𝑙𝑒𝑖 +
                     ∑ 𝛽r ∗  𝑟𝑒𝑔𝑖𝑜𝑛r
24
r=0 + θ ∗ 𝑦𝑒𝑎𝑟𝑖 +  𝜅 ∗ 𝑚𝑟𝑎𝑡𝑒𝑖 + ∑ 𝜌𝑎
9
𝑎=0 ∗ 𝑎𝑔𝑒𝑔𝑟𝑜𝑢𝑝𝑎 ∗ 𝑦𝑒𝑎𝑟𝑖  +
 𝜔 ∗ 𝑦𝑒𝑎𝑟𝑖 ∗ 𝑚𝑟𝑎𝑡𝑒𝑖  +  𝜓 ∗ 𝑎𝑔𝑒𝑔𝑟𝑜𝑢𝑝𝑖 ∗ 𝑚𝑟𝑎𝑡𝑒𝑖 + 𝑖 
 
The first, identified by coefficient (𝜓), aims at capturing the downward pressure of age on the 
death-related costs as explained above. The second, measured in coefficient (𝜔), displays the 
behaviour of mortality rates over time and the correspondent impact on average expenditures. 
(Gregersen 2014) 
Finally, all equations of Models A to C will be run using robust stand errors to correct for the 




The most interesting variables to have a look at before performing the steepening analysis itself 
are “age” and “pay_int” that returns the expenditure dimension. Over the 10 years, there was an 
increase on the mean age of patients, ranging from 49 years-old in 2009 to 53 in 2018, without 
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excluding the birth cases from the sample. Though these values are surely affected by the absolute 
decrease in the number of births, they can also be reflecting the presence of ageing on 
hospitalizations scenario. With a different perspective, the two histograms below demonstrate the 
episodes density distribution of variable “agegroup” over the sample but using as time unit two 
periods – from 2009 to 2013 and from 2014 to 2018.  
  
On the left, all observations were included, and it is clear the increase in the percentage of patients 
with more than 55 years-old on the second period, whereas the weight of relative younger cohorts 
decreased from the first period. On histogram plotted on the right, episodes belonging to DRG 14 
and 15 were excluded from the sample. Both trends continued to be observed, however, with less 
prominence. In absolute terms, the number of observations for the years in the first period is always 
higher than in the second, so if one should look to the evolution of total episodes per each age 
group, it is not possible to confirm an increase from 2009 to 2018. (Table 2)  
Focusing now on the expenditures dimension, its assessment must be done in two stages due to 
the reforms made in the DRG coding system explained in section III. Paying attention first to the 
original dataset that uses three different codes, in Table 3, the variable “pay_int” does not show 
Figure 1 : Episodes histograms by age groups  
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an increase in the mean values for though the period, just as “age” did. The highest value for 
average was registered in 2011, whereas the lowest corresponds to 2014, with an average of 
1944.4€. The opposite can be concluded if all episodes follow the same reference price table. For 
the year of 2009, the average inpatient expenditure was close to 2 590€ and by 2018 the value 
raised to 3029€.  
Though there were two changes in “prices”, the revision undertaken in 2015 produced a much 
significant impact on the average price level. By looking to Table 1, the average price level of 
almost all MDC increased from 2009 to 2018, however, results on the original dataset showed the 
opposite trend. This discrepancy relies on the relatively higher cost associated with more severe 
levels of each DRG code that pushed the overall average price of the group up. As most inpatient 
care episodes can be classified as having minor or moderate levels of severity, the average patient 
expenditure displayed relative lower cost weights comparing with previous versions. Nonetheless, 
it seems clear results on steepening will largely be influenced by the control for this “price” effect 
or not.  
Though these results are already important, examining the behaviour of per capita health care 
expenditures here named “Totexp_pc” should give a hint on the steepening hypothesis – if total 
expenditure per capita is proportionality higher for older age-groups in second period then it is 
quite possible that the steepening hypothesis is valid. “Totexp_pc” was generated by aggregating 
per year the total expenditures in “pay_int” for each age group and region and dividing it by the 






The figures above show per capita expenditures by age groups in the two periods considered. Once 
again, the price effect has been taken into account and results demonstrate different scenarios. On 
the left, per capita expenditures for older people did not increased in the last five years as in 
comparison with the first period, something that would predict a rejection of the steepening 
hypothesis. On the second graph, the opposite is observed as per capita costs seem to have a slight 
increase on the second period for age groups above 65 years old.  
Concerning the demographic variables for the number of inhabitants and the number of decedents 
that were retrieved from PORDATA, the comparison between the two periods is shown in Table 
4. From the first to the second period, there was a general decrease of mortality levels for all age 
groups, excepting for children aged between 0 and 4 years old. However, in absolute terms, the 
total number of decedents increased on period 2, whereas total population was higher on the period 
1. These results are consistent with the literature discussed above.  
Additionally, preliminary results on the impact of age and time on mortality changes were obtained 
by running (5). Following prior predictions, changes in mortality are negatively affected by 
Figure 3 - Total per capita expenditures by age groups (in €) 
(with price correction) 
 




changes occurred in age groups throughout the years considered, as the coefficient on 
“AgegxYear” is negative but statistically significant. This result reflects people living longer 
nowadays, showed by larger number of individuals in the older age cohorts, and although 
coefficients are quite small, they will be considered further along when testing for steepening under 
the rule in (6). (Table 5)  
 
STEEPENING RESULTS 
Model A  
The percentage of the per capita health care expenditures for older individuals aged above 65 years 
old has increased from 2009 to 2018. Based on the equation on Model A, the coefficient of interest 
is positive and statistically significant showing that, on average ceteris paribus, the ratio between 
elderly per capita expenses and the remaining population increased 15% from 2009 to 2018. On 
the other hand, acknowledging for the price effect, the ratio between per capita expenses for old 
and young, over the 10 years, has grew solely 4,8%, on average c.p.. 
Despite the overall increase of this ratio, annual results on Ratio A show there is evidence for a 
continuous growth in the ratio between old and young health care expenditures, apart from years 
2010, 2011 and 2014 that registered a lower value relative to the homologous. Correcting for the 
price effect does not change the conclusions for the first five years. However, for the remaining 
years, these ratios were relatively smaller indicating weaker effects of steepening, with the 
exception of 2015 that listed a decrease from the year before. (Table 7)  
With results on Model A coefficient, it is not possible to reject the steepening hypothesis from 
2009 to 2018, in both scenarios. Only when extending the analysis to a yearly basis, it possible to 
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conclude the non-linear growth of Ratio A that leads to the hypothesis rejection in those 
exceptional years.   
 
Model B 
Within this framework each age group will have a coefficient associated since Ratio B was 
computed for all cohorts with the exception of the benchmark group 5-9 years old. For age groups 
above 50 years old, all “year” coefficients are statistically significant and display an increasing 
trend as age increases, apart from the >85 cohort. The highest value is registered for individuals 
aged between 80 and 84 years old, as their per capita expenditures grew, on average, c.p., 1.1 times 
more than the reference group. (Table 8) 
On a second scenario with the correction for the price effect, coefficients show smaller yearly 
growth rates for all age groups and the highest value is now registered for individuals aged between 
75 and 79 years old, as the per capita expenditures for these individuals grew 0.6 times more than 
for per capita expenses for the reference age group, on average c.p.. 
These results do not reject the steepening hypothesis once again, as per capita expenditures for 
older groups of the population grew faster than for younger groups, in relative terms over the 10 







Model C  
As described in section IV, this last model develops a more complex analysis of the steepening 
definition by suggesting a non-linear relationship between the variables of interest and the 
inclusion of the impact of mortality rates on health care expenditures behaviour. Just as before, 
regressions were run twice to account for the correction in the price level. 
Common to (3) and (7), there is evidence that support a marginal decrease in the level of health 
care expenditures for female individuals, in comparison to men. In addition, when considering 
gender discrepancies within each age cohort performance, for women with more than 50 years old, 
the marginal decrease in the level of care spending is even larger comparing with men in the same 
age group. These results hold even when the price effect is controlled for. 
Regarding age alone, coefficient results suggest for positive and significant impact of the variable 
“agegroup” on expenditures. More importantly, this effect is relatively small for individuals aged 
below 50 years old, with the exception of children under 5, and starts to increase gradually as 
cohorts get older reaching maximum values in individuals aged above 80. Acknowledging the 
price effect seems to have almost no influence in the statistical inference of these coefficients.  
Focusing now on the coefficient of interest for the steepening analysis (𝜌𝑎), its interpretation 
changes from (3) to the remaining. On the first column of Table 9 and Table 10, the correspondent 
values represent the deviation in growth rates for the particular age group and younger groups 
(<50). Coefficients are small and in the vast majority not statistically significant, indicating that 
there is no evidence that health care expenditures increased faster for older cohorts. In the first 
scenario, for each 1€ increase on health care expenditures of younger individuals, per capita 
expenditures for people with 80 or more years old have increased, on average c.p., 4.8€. When the 
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price effect is accounted for, the marginal increase of per capita health care expenditures of the 
oldest cohort is reduced to 2.6€, for each 1€ increase in younger age groups, on average c.p.. 
Given these results and following the rule defined in (6), there is no statistical evidence that 
supports the existence of steepening.  
On the second regression of (3), the remaining annual growth rates were included to allow for a 
different interpretation of the coefficients and mortality rate variables were excluded. Now, instead 
of having comparisons between old and young, all expenditures growth rates are given as a 
deviation from the annual growth rate of health care expenditures of individuals between 5-9 years 
old. Once again, the larger relative increases have occurred in older cohorts for ages above 50 and 
in the youngest group. For instance, in comparison with a 1€ increase in the benchmark group per 
capita expenditures, for people with 80 and more years old, the marginal increase in per capita 
annual health care expenditure corresponded to, on average c.p, 8.2€. This value decreases to 5.6€ 
when correcting for changes in prices.  
Coefficients on the yearly rates increased from the first to the second regression, suggesting that 
the omission of the mortality levels might overestimate the growth of health care expenditures, at 
least for older age groups.  
Within this framework, there is statistical evidence to not reject the occurrence of steepening in 
the last two age cohorts as (𝜌80+ −  𝜌70 > 0) and (𝜌70 −  𝜌60 > 0) , in the first scenario. However, 
once the price effect is accounted, the existence of steepening extends to the age group 60, as well.   
Focusing on the model suggested by (Gregersen 2014) , results on the last four columns differ on 
the inclusion of the interaction term “YearxMrate” and in both cases mortality rate is only  
included to the power of 1, as the author did not find evidence to pursue with the polynomial form. 
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Results on annual growth rates (𝜌𝑎) decreased from the previous regression as it should be 
expected by adding again the mortality effect. Besides, the coefficient on “AgegxMrate” 
displayed a significant and negative result suggesting that the initial suspicious on death-related 
costs being a decreasing function of age could be correct.  
This time, the correction for changes in prices dictated different results for the presence of 
steepening. When excluding the interaction term between year and mortality, from Table 9, there 
is only significant evidence for the fastest growth of health care expenditures of individuals aged 
above 80, when in comparison with the reference group. However, from Table 10, the steepening 
hypothesis is not rejected for cohorts 60 and 70.  
Once all variables of equation (7) are included, the yearly growth rates of expenditures declined 
even more, in particular for the older cohorts that showed negative deviations from the reference 
group rate. This might indicate that a significant share of the growth in health care expenditures 
for these individuals can highly be related to the decrease in the mortality levels registered 
throughout the years, as the coefficient on “YearxMrate” is positive.  
Following the rule of thumb for the hypothesis testing, steepening is rejected as there is no 











VI. DISCUSSION AND CONCLUSION 
With the ongoing demographic transition occurring in most of the countries, concerns whether 
relatively older populations might impose additional pressure on health care systems worldwide 
have highlighted the long-term discussion on the impact of age, and consequently general 
population ageing, on health care expenditures. Under this context, Portugal is no exception as the 
country has now one of the largest shares of elderly population within the EU-27, estimated to 
increase in the years to come as well as a consistent increase in health care spending by the NHS 
over the last few decades. In this sense, the goal of the present work was to apply the concept of a 
steepening study to the Portuguese case and provide insights on what was the impact of ageing on 
NHS inpatient health care expenditures between 2009-2018 and derive conclusions for the next 
years.  
Data on public hospital episodes showed an increase in the average age of patients over the period, 
as a larger percentage of individuals with more than 50 years old received inpatient care in the last 
five years in analysis. Contradictory to what was expected, average annual health care expenditures 
did not increase during the same period partially due to the changes made in the DRG coding 
system used as cost referencing to these hospitals. Once all records were standardized to the same 
price level, results on the average and per capita health care expenditures revealed a general 
increase from 2009 to 2018, reaching its maximum in 2017. 
With respect to the existence of steepening, the three models chosen to perform the study had 
picked on different definitions of the term which also meant risking having ambiguous 
conclusions. The first approach applied a simple threshold between old and young and tested for 
the ratio on per capita health care expenditures between the two groups and how it evolved through 
the period. Within this framework, there was evidence to not reject the steepening hypothesis from 
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2009 to 2018. On the second model, the evaluation was made using age cohorts of five years each 
to allow for more flexibility in results. Taking as reference children aged between 5 and 9 years 
old, the relative expenditures growth rates for age groups above 50 years old except the last (>85), 
specified significant gradual increases suggesting once again the fastest growth of health care 
expenditures of elder groups in comparison with younger. In both models, the correction for the 
price effect derived the same conclusions on the original hypothesis though with less prominent 
annual growth rates. 
For the third model, health care expenditures were defined not only as a function of age and time 
but also of mortality levels. Since 2009, Portuguese mortality rates decreased in great share due to 
expansion in the length of life. The addition of mortality-related coefficients led to a significant 
reduction on the yearly growth rates of per capita health care expenditures, in particular, for age 
groups above 50 years old, reflecting that part of the annual increases in health care expenditures 
could somehow be affected by the reductions in mortality levels.   
With respect to the conclusions on the existence of steepening, the price effect played a 
distinguished role. On one hand, neglecting to correct for the changes occurred in the price level, 
led to the non-rejection of the hypothesis solely for the oldest age group (+80). On the other, when 
all episodes were standardized to the same price level, there was statistical evidence for the fastest 
growth of health care expenditures of individuals aged between 60 and 79 years old, not rejecting 
the presence of steepening though with lower results.   
The repercussions of these inferences must be considered carefully when making any prediction 
on future health care expenditures for Portugal once two distinct scenarios are drawn depending 
on the cost-drivers contemplated. Furthermore, it is important to highlight this study only 
considered one type of health care service, so it is not possible to judge or predict how care 
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expenditures will evolve for the remaining components of the total national expenditure. Extending 
to other sectors, such as long-term care or ambulatory care, could largely yield different results on 
the existence of steepening, especially in case there is a substitution and/or complementary effect 
between any of these services.  
Another major limitation of this work is the use of DRG relative weights as a proxy for inpatient 
health care expenditures. By definition, these weights reflect the estimated cost for a specific 
treatment on an average patient, as such, attributing the same cost regardless of age can represent 
an underestimation of the actual expenditures for the elderly as typically these individuals develop 
worst health conditions and required extra care. (Gregersen 2014) Though the opposite can occur 
for younger groups, divergences between age groups could affect conclusions on the steepening 
premise.  
In conclusion, evidence shows population ageing to have caused an acceleration on inpatient health 
care expenditures over time for individuals with more than 65 years old when age is the main 
explanatory variable. Once other determinants are included such as mortality levels, conclusions 
on the existence of steepening are reduced and only plausible for particular age cohorts, suggesting 
that a great share of the annual increases on per capita health care expenditures for these groups 
are related to the relatively higher costs with death. As these costs tend to decrease with age, the 
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0. 	Pre-MDC € 50.035 € 45.216 -9,6% € 37.421 -17,2% -25,2%
1.Diseases and Disorders of the Nervous System € 3.263 € 4.724 44,8% € 6.433 36,2% 97,1%
2.Diseases and Disorders of the Eye € 1.729 € 2.042 18,1% € 3.718 82,1% 115,0%
3.Diseases and Disorders of the Ear, Nose, Mouth And Throat € 2.401 € 1.510 -37,1% € 6.383 322,8% 165,8%
4.Diseases and Disorders of the Respiratory System € 2.972 € 3.196 7,5% € 4.483 40,3% 50,8%
5.Diseases and Disorders of the Circulatory System € 7.965 € 5.221 -34,5% € 7.121 36,4% -10,6%
6.Diseases and Disorders of the Digestive System € 3.481 € 1.974 -43,3% € 4.549 130,4% 30,7%
7.Diseases and Disorders of the Hepatobiliary System And Pancreas € 4.863 € 3.813 -21,6% € 5.498 44,2% 13,1%
8.Diseases and Disorders of the Musculoskeletal System And Connective Tissue € 4.336 € 2.557 -41,0% € 7.777 204,2% 79,3%
9.Diseases and Disorders of the Skin, Subcutaneous Tissue And Breast € 2.390 € 1.918 -19,7% € 5.357 179,3% 124,1%
10.Diseases and Disorders of the Endocrine, Nutritional And Metabolic System € 3.677 € 2.403 -34,6% € 5.513 129,4% 49,9%
11.Diseases and Disorders of the Kidney And Urinary Tract € 2.015 € 1.729 -14,2% € 5.592 223,4% 177,5%
12.Diseases and Disorders of the Male Reproductive System € 1.921 € 1.446 -24,7% € 6.870 374,9% 257,6%
13.Diseases and Disorders of the Female Reproductive System € 2.444 € 1.412 -42,2% € 5.477 287,8% 124,1%
14.Pregnancy, Childbirth And Puerperium € 1.304 € 597 -54,2% € 2.265 279,1% 73,7%
15.Newborn And Other Neonates (Perinatal Period) € 14.280 € 20.698 44,9% € 16.786 -18,9% 17,5%
16.Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders € 2.593 € 2.296 -11,5% € 5.096 122,0% 96,5%
17.Myeloproliferative DDs (Poorly Differentiated Neoplasms) € 7.809 € 5.498 -29,6% € 8.687 58,0% 11,2%
18.Infectious and Parasitic DDs (Systemic or unspecified sites) € 2.668 € 3.784 41,8% € 5.118 35,3% 91,8%
19.Mental Diseases and Disorders € 2.380 € 2.239 -5,9% € 4.178 86,6% 75,6%
20.Alcohol/Drug Use or Induced Mental Disorders € 1.184 € 1.294 9,3% € 3.061 136,6% 158,6%
21.Injuries, Poison And Toxic Effect of Drugs € 2.121 € 2.102 -0,9% € 3.967 88,7% 87,1%
22.Burns € 14.486 € 15.834 9,3% € 23.387 47,7% 61,4%
23.Factors Influencing Health Status and Other Contacts with Health Services € 2.016 € 3.139 55,7% € 6.226 98,4% 208,9%
24.Multiple Significant Trauma € 8.554 € 14.443 68,8% € 4.915 -66,0% -42,5%
25.Human Immunodeficiency Virus Infection € 9.755 € 14.828 52,0% € 12.698 -14,4% 30,2%
MDC* Overall
* Major Diagnostic Category 
Table 2 – Inpatient health care episodes by age groups 
2009 2012 2015 2018 2009 2012 2015 2018
0-4 101.758 104.592 62.135 57.425 0-4 26.724 28.144 16.631 15.347
5-9 13.885 12.205 6.838 5.414 5-9 13.885 12.205 6.838 5.414
10-14 10.201 11.000 5.987 4.747 10-14 10.166 10.921 5.943 4.721
15-19 14.373 16.649 9.121 7.906 15-19 10.910 12.876 7.375 6.482
20-24 23.254 24.186 12.958 12.302 20-24 11.181 12.626 6.671 6.216
25-29 36.239 37.042 19.860 19.115 25-29 13.550 15.194 7.387 6.860
30-34 46.175 47.452 27.410 25.466 30-34 18.242 20.259 9.681 8.364
35-39 37.973 43.646 25.458 24.228 35-39 22.758 27.416 13.913 11.427
40-44 30.694 35.620 20.488 19.249 40-44 27.032 32.004 17.768 15.698
45-49 32.632 39.873 21.347 19.585 45-49 32.369 39.653 21.199 19.406
50-54 36.196 46.141 25.876 23.097 50-54 36.188 46.132 25.864 23.085
55-59 38.131 50.467 29.233 27.457 55-59 38.131 50.467 29.233 27.455
60-64 43.718 57.977 32.809 32.145 60-64 43.717 57.976 32.809 32.145
65-69 45.903 62.946 37.591 37.075 65-69 45.901 62.946 37.591 37.075
70-74 56.673 68.181 39.321 39.939 70-74 56.673 68.181 39.321 39.939
75-79 62.518 78.483 46.795 41.755 75-79 62.518 78.483 46.795 41.755
80-84 56.001 70.481 45.796 44.553 80-84 56.001 70.481 45.796 44.553
85-89 39.274 50.926 34.774 35.525 85-89 39.274 50.926 34.773 35.525
90-94 14.450 19.766 16.277 17.107 90-94 14.450 19.766 16.277 17.107
95-99 3.975 4.668 3.294 4.239 95-99 3.975 4.668 3.294 4.239
>100 - 493 414 429 >100 - 493 414 429
Total 744.023 882.794 523.782 498.758 Total 583.645 721.817 425.573 403.242

















Original With Price Correction
#Observations mean #Observations mean 
2009 744.023 2.590 744.023 2.590
2010 778.267 2.597 778.267 2.597
2011 891.142 2.803 891.142 2.803
2012 882.794 2.377 882.794 2.377
2013 626.913 2.350 662.746 2.338
2014 817.756 1.985 817.792 2.905
2015 523.782 1.944 523.762 2.822
2016 514.607 2.430 514.476 3.500
2017 499.286 2.470 498.779 3.521
2018 498.758 2.131 498.804 3.029
Total 6.777.328 23.678 6.812.585 28.483
Year
Table 3 - Average annual Health Care Expenditures on hospitalization episodes 
Table 4 - Descriptive statistics: demographic variables 
Dependent Variable Mortality Rate (Mortality Rate)² (Mortality Rate)³ (Mortality Rate)
4
Independent Variable Coefficient Std. er Coefficient Std. er Coefficient Std. er Coefficient Std. er
Year 0.000116*** (3.73e-05) 2.49e-05*** (8.13e-06) 3.88e-06*** (1.39e-06) 5.65e-07*** (2.14e-07)
Ageg x Year -7.63e-06*** (8.25e-07) -1.26e-06*** (1.80e-07) -1.92e-07*** (3.08e-08) -2.78e-08*** (4.74e-09)
Constant -0.00117*** (0.000405) -0.000358*** (8.83e-05) -5.48e-05*** (1.51e-05) -7.78e-06*** (2.33e-06)
N 2,469 2,469 2,469 2,469
R-Squared 0.990 0.961 0.909 0.837
*** p<0.01, ** p<0.05, * p<0.1
Standard errors in parentheses






Table 6 - Results on equation (1) 
Dependent Variable Ratio A
Independent Variables Coeff. Robust Std. er Coeff. Robust Std. er
year 0.149*** (0.0177) 0.048*** (0.0148)
Constant 294.728*** (35.5694) -92.001*** (29.7180)
Observations 250 250
R-Squared 0.611 0.522
*** p<0.01, ** p<0.05, * p<0.1
With Price Correction Original 
Table 8 - Results on equation (2) 
Ratio B
Variables 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 > 85
year 0.0270* - 0.0218*** 0.00987 0.0137 0.0184 0.0355** 0.0365** 0.0462 0.0607* 0.102*** 0.151*** 0.244*** 0.343*** 0.427*** 0.626*** 0.591*** 0.423***
(0.0140) - (0.00837) (0.0127) (0.0147) (0.0119) (0.0178) (0.0177) (0.0287) (0.0349) (0.0386) (0.0512) (0.0694) (0.0924) (0.105) (0.126) (0.155) (0.148)
Constant -52.07* 1 -42.87** -18.39 -25.90 -35.18 -69.64* -71.15** -90.11 -118.2* -199.7** -296.6*** -483.3*** -680.0*** -846.3*** -1,242*** -1,169*** -832.8***
(28.19) - (16.86) (25.66) (29.62) (23.90) (35.86) (35.67) (57.75) (70.30) (77.65) (103.1) (139.8) (186.1) (210.7) (254.4) (312.8) (297.5)
Observations 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
R-squared 0.160 0.142 0.182 0.147 0.257 0.154 0.289 0.206 0.152 0.221 0.233 0.210 0.215 0.224 0.262 0.249 0.232
(Agegroups)
Robust standard errors in parentheses
*** p<0.01, ** p<0.05, * p<0.1
With Price Correction 
Ratio B
Variables 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 > 85
year 0.114*** - 0.0214** 0.0157 0.0184 0.0133 0.0265 0.0301 0.0372 0.0496 0.0869** 0.123** 0.192*** 0.317*** 0.524*** 0.868*** 1.123*** 0.945***
(0.0149) - (0.00924) (0.0136) (0.0156) (0.0126) (0.0168) (0.0185) (0.0242) (0.0304) (0.0347) (0.0478) (0.0610) (0.0845) (0.0877) (0.121) (0.147) (0.142)
Constant -227.1*** 1 -41.90** -30.00 -35.40 -24.89 -51.50 -58.22 -71.87 -95.67 -169.4** -240.3** -377.9*** -626.6*** -1,041*** -1,728*** -2,236*** -1,882***
(30.06) - (18.61) (27.36) (31.35) (25.30) (33.84) (37.23) (48.65) (61.26) (69.89) (96.25) (122.9) (170.1) (176.5) (244.6) (296.2) (285.0)
Observations 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
R-squared 0.332 0.168 0.157 0.187 0.336 0.189 0.356 0.304 0.227 0.413 0.348 0.365 0.433 0.537 0.566 0.613 0.598
Original
(Agegroups)
Robust standard errors in parentheses












Table 7 - Ratio between per capita health care expenditures of elderly and young population 






Variable Per capita expenditures  
  ln (Totexp_pc) 
Equation (3) 
 (3)   (7)  
(7)  Excluding Mortality  
Excluding interaction 




Coeff. Std.Error   Coeff. Std.Error   Coeff. Std.Error   Coeff. Std.Error 
            
female (δ) -0.277*** (0.0549)  -0.277*** (0.0552)  -0.277*** (0.0550)  -0.277*** (0.0551) 
Agegroup (𝜐)  





0-4 0.806*** (0.0558)  0.633*** (0.0880)  0.589*** (0.0939)  0.606*** (0.0935) 
5-9 -   -   -   -  
10-19 0.0357 (0.0513)  -0.0462 (0.0917)  -0.0494 (0.0909)  -0.0467 (0.0910) 
20-29 0.142*** (0.0539)  0.158* (0.0909)  0.143 (0.0924)  0.155* (0.0925) 
30-39 0.389*** (0.0565)  0.386*** (0.0896)  0.367*** (0.0935)  0.391*** (0.0933) 
40-49 0.852*** (0.0749)  0.946*** (0.0881)  0.921*** (0.104)  0.988*** (0.104) 
50-59 1.305*** (0.148)  1.487*** (0.0900)  1.491*** (0.126)  1.648*** (0.127) 
60-69 1.704*** (0.242)  1.993*** (0.0885)  2.127*** (0.152)  2.481*** (0.163) 
70-79 2.505*** (0.401)  2.317*** (0.0923)  3.043*** (0.211)  4.040*** (0.279) 
80+ 4.033*** (0.824)  2.539*** (0.111)  6.700*** (0.723)  10.76*** (1.039) 
            
(𝜏)            
FemalexAgeg0 0.0819 (0.0745)  0.0819 (0.0748)  0.0819 (0.0743)  0.0819 (0.0744) 
FemalexAgeg10 0.0987 (0.0738)  0.0987 (0.0746)  0.0987 (0.0740)  0.0987 (0.0740) 
FemalexAgeg20 0.0209 (0.0756)  0.0209 (0.0758)  0.0209 (0.0755)  0.0209 (0.0756) 
FemalexAgeg30 0.159** (0.0749)  0.159** (0.0748)  0.159** (0.0748)  0.159** (0.0748) 
FemalexAgeg40 0.0680 (0.0735)  0.0680 (0.0739)  0.0680 (0.0736)  0.0680 (0.0736) 
FemalexAgeg50 -0.144* (0.0738)  -0.144* (0.0743)  -0.144* (0.0740)  -0.144* (0.0738) 
FemalexAgeg60 -0.237*** (0.0741)  -0.237*** (0.0744)  -0.237*** (0.0741)  -0.237*** (0.0737) 
FemalexAgeg70 -0.181** (0.0792)  -0.181** (0.0801)  -0.181** (0.0795)  -0.181** (0.0782) 
FemalexAgeg80 -0.0331 (0.0885)  -0.0269 (0.0985)  -0.0315 (0.0940)  -0.0353 (0.0923)             
Year (𝜃) -0.0748*** (0.00430)  -0.0911*** (0.0110)  -0.0907*** (0.0108)  -0.0914*** (0.0108) 
  
 
         
(𝜌)            
YearxAgeg0   
 0.0476*** (0.0152)  0.0482*** (0.0149)  0.0428*** (0.0150) 
YearxAgeg10   
 0.0195 (0.0157)  0.0194 (0.0155)  0.0186 (0.0155) 
YearxAgeg20   
 0.00195 (0.0156)  0.00252 (0.0154)  -0.000743 (0.0154) 
YearxAgeg30   
 0.0114 (0.0152)  0.0122 (0.0150)  0.00600 (0.0151) 
YearxAgeg40   
 0.00700 (0.0153)  0.00749 (0.0152)  -0.00993 (0.0155) 
YearxAgeg50 0.00364 (0.0116)  0.0180 (0.0156)  0.0176 (0.0154)  -0.0230 (0.0173) 
YearxAgeg60 0.0103 (0.0117)  0.0260* (0.0154)  0.0242 (0.0154)  -0.0633*** (0.0228) 
YearxAgeg70 0.0219 (0.0146)  0.0574*** (0.0158)  0.0458*** (0.0164)  -0.189*** (0.0474) 
YearxAgeg80 0.0479*** (0.0151)  0.0823*** (0.0179)  0.0509*** (0.0190)  -0.885*** (0.178) 
            
mrate (𝜅) 71.38** (30.19)   
  65.42 (53.08)  39.38 (51.10) 
mrate2 -3,897*** (936.9)   
       
mrate3 50,884*** (9,752)   
       
mrate4 -202,031*** (33,914)   
       
            
AgegxMrate (𝜓)  
  
 
  -1.290* (0.702)  -1.433** (0.674) 
YearxMrate (𝜔)  
  
 
     8.774*** (1.723) 
            
Constant 3.710*** (0.0481)  3.814*** (0.0656)  3.756*** (0.0659)  3.762*** (0.0659) 
Observations 4,998   4,998   4,998   4,998  
R-squared 0.794     0.780     0.788     0.792   
Robust standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
Table 9 - Results on regressions (3) and (7) 
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Variable Per capita expenditures  
  ln (Totexp_pc) 
Equation (3) 
 (3)  (7)  
(7)  Excluding Mortality   
Excluding interaction 




Coeff. Std.Error   Coeff. Std.Error 
  
Coeff. Std.Error   Coeff. Std.Error 
            
female (δ) -0.270*** (0.0570)  -0.270*** (0.0574)  -0.270*** (0.0572)  -0.270*** (0.0572) 
Agegroup (𝜐)            
0-4 0.685*** (0.0566)  0.667*** (0.0869)  0.615*** (0.0931)  0.634*** (0.0924) 
5-9 -   -   -   -  
10-19 0.0284 (0.0525)  -0.0523 (0.0894)  -0.0563 (0.0889)  -0.0533 (0.0890) 
20-29 0.140** (0.0542)  0.134 (0.0883)  0.114 (0.0899)  0.128 (0.0899) 
30-39 0.403*** (0.0574)  0.379*** (0.0875)  0.352*** (0.0917)  0.378*** (0.0914) 
40-49 0.857*** (0.0753)  0.955*** (0.0858)  0.910*** (0.102)  0.985*** (0.101) 
50-59 1.248*** (0.146)  1.492*** (0.0876)  1.460*** (0.125)  1.633*** (0.124) 
60-69 1.599*** (0.241)  1.997*** (0.0863)  2.064*** (0.151)  2.452*** (0.160) 
70-79 2.339*** (0.402)  2.354*** (0.0911)  2.923*** (0.210)  4.013*** (0.281) 
80+ 3.949*** (0.829)  2.615*** (0.111)  6.287*** (0.716)  10.72*** (1.075) 
            
(𝜏)            
FemalexAgeg0 0.117 (0.0760)  0.117 (0.0768)  0.117 (0.0763)  0.117 (0.0763) 
FemalexAgeg10 0.106 (0.0755)  0.106 (0.0760)  0.106 (0.0757)  0.106 (0.0757) 
FemalexAgeg20 0.0639 (0.0761)  0.0639 (0.0763)  0.0639 (0.0761)  0.0639 (0.0761) 
FemalexAgeg30 0.179** (0.0759)  0.179** (0.0759)  0.179** (0.0759)  0.179** (0.0759) 
FemalexAgeg40 0.0637 (0.0746)  0.0637 (0.0749)  0.0637 (0.0747)  0.0637 (0.0746) 
FemalexAgeg50 -0.141* (0.0747)  -0.141* (0.0751)  -0.141* (0.0749)  -0.141* (0.0747) 
FemalexAgeg60 -0.220*** (0.0750)  -0.220*** (0.0752)  -0.220*** (0.0750)  -0.220*** (0.0745) 
FemalexAgeg70 -0.160** (0.0796)  -0.160** (0.0804)  -0.160** (0.0799)  -0.160** (0.0784) 
FemalexAgeg80 -0.00152 (0.0882)  0.00428 (0.0963)  0.00428 (0.0929)  0.00428 (0.0907) 
            
Year (𝜃) -0.0160*** (0.00419)  -0.0300*** (0.0108)  -0.0294*** (0.0106)  -0.0302*** (0.0106) 
            
(𝜌)            
YearxAgeg0    0.0148 (0.0150)  0.0154 (0.0148)  0.00944 (0.0148) 
YearxAgeg10    0.0195 (0.0153)  0.0193 (0.0151)  0.0184 (0.0151) 
YearxAgeg20    0.00780 (0.0150)  0.00855 (0.0149)  0.00494 (0.0149) 
YearxAgeg30    0.0180 (0.0147)  0.0190 (0.0147)  0.0122 (0.0147) 
YearxAgeg40    0.0111 (0.0148)  0.0121 (0.0148)  -0.00719 (0.0151) 
YearxAgeg50 0.0134 (0.0112)  0.0248* (0.0151)  0.0247* (0.0149)  -0.0202 (0.0167) 
YearxAgeg60 0.0210* (0.0113)  0.0334** (0.0150)  0.0322** (0.0150)  -0.0645*** (0.0219) 
YearxAgeg70 0.0160 (0.0141)  0.0480*** (0.0155)  0.0387** (0.0160)  -0.221*** (0.0457) 
YearxAgeg80 0.0261* (0.0144)  0.0562*** (0.0177)  0.0281 (0.0181)  -1.007*** (0.171) 
            
mrate (𝜅) 82.82*** (30.26)     78.19 (53.68)  49.07 (50.43) 
mrate2 -4,084*** (930.6)          
mrate3 51,546*** (9,511)          
mrate4 -200,416*** (32,521)          
            
AgegxMrate (𝜓)       -1.394** (0.709)  -1.541** (0.669) 
YearxMrate (𝜔)          9.712*** (1.650) 
            
Constant 3.652*** (0.0492)  3.741*** (0.0650)  3.689*** (0.0655)  3.696*** (0.0654) 
Observations 4,936   4,936   4,936   4,936  
R-squared 0,789     0.776     0.782     0.788   
Robust standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
